ASH 2015: Highs And Lows In CLL
This article was originally published in Scrip
Executive Summary
A number of companies reported positive developments for products being developed for, or seeking label expansions in, chronic lymphatic leukemia (CLL) at the American Society of Hematology (ASH) annual meeting in Orlando, Florida, but Gilead Sciences kept the balance with a poor prognosis for Zydelig (idelalisib) as a future first-line agent.